RSVVW 2021 – Pfizer gets maternal
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
Bavarian Nordic gets a vaccine booster
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
Bavarian’s chance to draw a line under oncology
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Go or no go? Novo awaits call on oral sema
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
